These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 36524911)

  • 1. The prophylactic efficacy of Anatolian propolis in individuals at high risk of COVID-19.
    Guler E; Bilir O; Osman Kocak A; Atas I; Tanugur Samanci AE
    Eur Rev Med Pharmacol Sci; 2022 Dec; 26(2 Suppl):53-60. PubMed ID: 36524911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A structured summary of a study protocol for a randomised controlled trial.
    Miryan M; Soleimani D; Dehghani L; Sohrabi K; Khorvash F; Bagherniya M; Sayedi SM; Askari G
    Trials; 2020 Dec; 21(1):996. PubMed ID: 33272309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesic effect of Anatolian propolis in mice.
    Kamburoğlu K; Özen T
    Agri; 2011 Apr; 23(2):47-50. PubMed ID: 21644103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial.
    Silveira MAD; De Jong D; Berretta AA; Galvão EBDS; Ribeiro JC; Cerqueira-Silva T; Amorim TC; Conceição LFMRD; Gomes MMD; Teixeira MB; Souza SP; Santos MHCAD; San Martin RLA; Silva MO; Lírio M; Moreno L; Sampaio JCM; Mendonça R; Ultchak SS; Amorim FS; Ramos JGR; Batista PBP; Guarda SNFD; Mendes AVA; Passos RDH;
    Biomed Pharmacother; 2021 Jun; 138():111526. PubMed ID: 34311528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back to the basics: Propolis and COVID-19.
    Bachevski D; Damevska K; Simeonovski V; Dimova M
    Dermatol Ther; 2020 Jul; 33(4):e13780. PubMed ID: 32506775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propolis and Diet Rich in Polyphenols as Cariostatic Agents Reducing Accumulation of Dental Plaque.
    Kurek-Górecka A; Walczyńska-Dragon K; Felitti R; Baron S; Olczyk P
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of systemic Anatolian propolis administration on a rat-irradiated osteoradionecrosis model.
    Çolak S; Erdil A; Gevrek F
    J Appl Oral Sci; 2023; 31():e20230231. PubMed ID: 37909529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment.
    Ripari N; Sartori AA; da Silva Honorio M; Conte FL; Tasca KI; Santiago KB; Sforcin JM
    J Pharm Pharmacol; 2021 Mar; 73(3):281-299. PubMed ID: 33793885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Activity of Bee Products.
    Kontogiannis T; Dimitriou TG; Didaras NA; Mossialos D
    Curr Pharm Des; 2022; 28(35):2867-2878. PubMed ID: 36173050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.
    Molino S; Pisarevsky A; Mingorance FL; Vega P; Stefanolo JP; Repetti J; Ludueña G; Pepa P; Olmos JI; Fermepin MR; Uehara T; Villapol S; Savidge T; Treangen T; Viciani E; Castagnetti A; Piskorz MM
    Trials; 2021 Apr; 22(1):310. PubMed ID: 33910614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).
    Lima WG; Brito JCM; da Cruz Nizer WS
    Phytother Res; 2021 Feb; 35(2):743-750. PubMed ID: 32945590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Propolis on Viral Respiratory Diseases.
    Ożarowski M; Karpiński TM
    Molecules; 2023 Jan; 28(1):. PubMed ID: 36615554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.